메뉴 건너뛰기




Volumn 12, Issue 9, 2015, Pages 547-558

Erratum : Cardiotoxicity of anticancer treatments (Nature Reviews Cardiology (2015), 12, (547-558)) doi:10.1038/nrcardio.2015.65);Cardiotoxicity of anticancer treatments

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CAPECITABINE; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; IMATINIB; LAPATINIB; MITOXANTRONE; PERTUZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

EID: 84939776300     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2015.133     Document Type: Erratum
Times cited : (348)

References (106)
  • 2
    • 0015849162 scopus 로고
    • A clinicopathologic analysis of adriamycin cardiotoxicity
    • Lefrak, E. A., Pitha, J., Rosenheim, S. & Gottlieb, J. A. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32, 302-314 (1973).
    • (1973) Cancer , vol.32 , pp. 302-314
    • Lefrak, E.A.1    Pitha, J.2    Rosenheim, S.3    Gottlieb, J.A.4
  • 3
    • 84872599189 scopus 로고    scopus 로고
    • Radiation-related mortality from heart disease and lung cancer more than 20 years after radiotherapy for breast cancer
    • Henson, K. E., McGale, P., Taylor, C. & Darby, S. C. Radiation-related mortality from heart disease and lung cancer more than 20 years after radiotherapy for breast cancer. Br. J. Cancer 108, 179-182 (2013).
    • (2013) Br. J. Cancer , vol.108 , pp. 179-182
    • Henson, K.E.1    McGale, P.2    Taylor, C.3    Darby, S.C.4
  • 4
    • 32144448027 scopus 로고    scopus 로고
    • Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment
    • Ewer, M. et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J. Clin. Oncol. 23, 7820-7826 (2005).
    • (2005) J. Clin. Oncol , vol.23 , pp. 7820-7826
    • Ewer, M.1
  • 5
    • 84877741007 scopus 로고    scopus 로고
    • The hibernating myocardium: Current concepts, diagnostic dilemmas, and clinical challenges in the post-STICH era
    • Shah, B. N., Khattar, R. S. & Senior, R. The hibernating myocardium: current concepts, diagnostic dilemmas, and clinical challenges in the post-STICH era. Eur. Heart J. 34, 1323-1336 (2013).
    • (2013) Eur. Heart J. , vol.34 , pp. 1323-1336
    • Shah, B.N.1    Khattar, R.S.2    Senior, R.3
  • 6
    • 79955777649 scopus 로고    scopus 로고
    • Ku70 and Rad51 vary in their importance for repair of doxorubicin-versus etoposide-induced DNA damage
    • Schonn, I., Hennesen, J. & Dartsch, D. C. Ku70 and Rad51 vary in their importance for repair of doxorubicin-versus etoposide-induced DNA damage. Apoptosis 16, 359-369 (2011).
    • (2011) Apoptosis , vol.16 , pp. 359-369
    • Schonn, I.1    Hennesen, J.2    Dartsch, D.C.3
  • 9
    • 74049092701 scopus 로고    scopus 로고
    • Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase
    • Kerkela, R. et al. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin. Transl. Sci. 2, 15-25 (2009).
    • (2009) Clin. Transl. Sci , vol.2 , pp. 15-25
    • Kerkela, R.1
  • 10
    • 19444378256 scopus 로고    scopus 로고
    • Type II chemotherapy-related cardiac dysfunction: Time to recognize a new entity
    • Ewer, M. S. & Lippman, S. M. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J. Clin. Oncol. 23, 2900-2902 (2005).
    • (2005) J. Clin. Oncol , vol.23 , pp. 2900-2902
    • Ewer, M.S.1    Lippman, S.M.2
  • 11
    • 84927671972 scopus 로고    scopus 로고
    • Cancer treatment-related cardiotoxicity: Current state of knowledge and future research priorities
    • Shelburne, N. et al. Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities. J. Natl. Cancer Inst. 106, dju232 (2014).
    • (2014) J. Natl. Cancer Inst , vol.106 , pp. dju232
    • Shelburne, N.1
  • 12
    • 84877995039 scopus 로고    scopus 로고
    • The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients
    • Hall, P. S., Harshman, L. C., Srinivas, S. & Witteles, R. M. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. JACC Heart Fail. 1, 72-78 (2013).
    • (2013) JACC Heart Fail , vol.1 , pp. 72-78
    • Hall, P.S.1    Harshman, L.C.2    Srinivas, S.3    Witteles, R.M.4
  • 13
    • 84923853767 scopus 로고    scopus 로고
    • Fluid retention associated with imatinib treatment in patients with gastrointestinal stromal tumor: Quantitative radiologic assessment and implications for management
    • Kim, K. W. et al. Fluid retention associated with imatinib treatment in patients with gastrointestinal stromal tumor: quantitative radiologic assessment and implications for management. Korean J. Radiol. 16, 304-313 (2015).
    • (2015) Korean J. Radiol , vol.16 , pp. 304-313
    • Kim, K.W.1
  • 14
    • 84904070535 scopus 로고    scopus 로고
    • Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: A comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events
    • Ewer, M. S. et al. Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events. Eur. J. Cancer 50, 2162-2170 (2014).
    • (2014) Eur. J. Cancer , vol.50 , pp. 2162-2170
    • Ewer, M.S.1
  • 15
    • 0026031848 scopus 로고    scopus 로고
    • Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood
    • Lipshultz, S. E. et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N. Engl. J. Med. 324, 808-815 (1999).
    • (1999) N. Engl. J. Med , vol.324 , pp. 808-815
    • Lipshultz, S.E.1
  • 16
    • 0018716636 scopus 로고
    • Risk factors for doxorubicin-induced congestive heart failure
    • Von Hoff, D. D. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 91, 710-717 (1979).
    • (1979) Ann. Intern. Med , vol.91 , pp. 710-717
    • Von Hoff, D.D.1
  • 19
    • 0038521374 scopus 로고    scopus 로고
    • Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials
    • Swain, S. M., Whaley, F. S. & Ewer, M. S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97, 2869-2879 (2013).
    • (2013) Cancer , vol.97 , pp. 2869-2879
    • Swain, S.M.1    Whaley, F.S.2    Ewer, M.S.3
  • 20
    • 84907352671 scopus 로고    scopus 로고
    • Prevention of anthracycline-induced cardiotoxicity
    • Vejpongsa, P. & Yeh, E. T. Prevention of anthracycline-induced cardiotoxicity. J. Am. Coll. Cardiol. 64, 936-945 (2014).
    • (2014) J. Am. Coll. Cardiol , vol.64 , pp. 936-945
    • Vejpongsa, P.1    Yeh, E.T.2
  • 21
    • 0018150114 scopus 로고
    • Distribution and antitumor activity of adriamycin given in a high-dose and a repeated low-dose schedule to mice
    • Pacciarini, M. A. et al. Distribution and antitumor activity of adriamycin given in a high-dose and a repeated low-dose schedule to mice. Cancer Treat. Rep. 62, 791-800 (1978).
    • (1978) Cancer Treat. Rep , vol.62 , pp. 791-800
    • Pacciarini, M.A.1
  • 22
    • 0020684494 scopus 로고
    • Effect of anthracycline antibiotics on oxygen radical formation in rat heart
    • Doroshow, J. H. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res. 43, 460-472 (1983).
    • (1983) Cancer Res , vol.43 , pp. 460-472
    • Doroshow, J.H.1
  • 23
    • 84869209094 scopus 로고    scopus 로고
    • Identification of the molecular basis of doxorubicin-induced cardiotoxicity
    • Zhang, S. et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med. 18, 1639-1642 (2012).
    • (2012) Nat. Med , vol.18 , pp. 1639-1642
    • Zhang, S.1
  • 24
    • 1542349778 scopus 로고    scopus 로고
    • Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes
    • Lim, C. C. et al. Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J. Biol. Chem. 279, 8290-8299 (2004).
    • (2004) J. Biol. Chem , vol.279 , pp. 8290-8299
    • Lim, C.C.1
  • 25
    • 33644806519 scopus 로고    scopus 로고
    • Protecting against anthracycline-induced myocardial damage: A review of the most promising strategies
    • Wouters, K. A. et al. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br. J. Haematol. 131, 561-578 (2005).
    • (2005) Br. J. Haematol , vol.131 , pp. 561-578
    • Wouters, K.A.1
  • 26
    • 84871560746 scopus 로고    scopus 로고
    • Using cardiac biomarkers and treating cardiotoxicity in cancer
    • Colombo, A. & Cardinale, D. Using cardiac biomarkers and treating cardiotoxicity in cancer. Future Cardiol. 1, 105-118 (2010).
    • (2010) Future Cardiol , vol.1 , pp. 105-118
    • Colombo, A.1    Cardinale, D.2
  • 27
    • 0021356510 scopus 로고
    • A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin
    • Ewer, M. S. et al. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. J. Clin. Oncol. 2, 112-117 (1984).
    • (1984) J. Clin. Oncol , vol.2 , pp. 112-117
    • Ewer, M.S.1
  • 28
    • 84906834548 scopus 로고    scopus 로고
    • Expert Consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
    • Plana, J. C. et al. Expert Consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiogr. 27, 911-939 (2014).
    • (2014) J. Am. Soc. Echocardiogr , vol.27 , pp. 911-939
    • Plana, J.C.1
  • 29
    • 80053539103 scopus 로고    scopus 로고
    • Adjuvant trastuzumab in HER2-positive breast cancer
    • Slamon, D. et al. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 365, 1273-1283 (2010).
    • (2010) N. Engl. J. Med , vol.365 , pp. 1273-1283
    • Slamon, D.1
  • 30
    • 41649083764 scopus 로고    scopus 로고
    • Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial
    • Perez, E. A. et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J. Clin. Oncol. 26, 1231-1238 (2008).
    • (2008) J. Clin. Oncol , vol.26 , pp. 1231-1238
    • Perez, E.A.1
  • 31
    • 29744442709 scopus 로고    scopus 로고
    • Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31
    • Tan-Chiu, E. et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J. Clin. Oncol. 23, 7811-7819 (2005).
    • (2005) J. Clin. Oncol , vol.23 , pp. 7811-7819
    • Tan-Chiu, E.1
  • 32
    • 79960013901 scopus 로고    scopus 로고
    • Onco-cardiology: The time has come
    • Yeh, E. T. Onco-cardiology: the time has come. Tex. Heart Inst. J. 38, 246-247 (2011).
    • (2011) Tex. Heart Inst. J. , vol.38 , pp. 246-247
    • Yeh E. ., T.1
  • 33
    • 53049098067 scopus 로고    scopus 로고
    • Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity
    • Fan, L. et al. Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity. Pharmacogenet. Genomics 18, 621-631 (2008).
    • (2008) Pharmacogenet. Genomics , vol.18 , pp. 621-631
    • Fan, L.1
  • 34
    • 77957306355 scopus 로고    scopus 로고
    • Cardiotoxicity of anticancer treatments: What the cardiologist needs to know
    • Ewer, M. S. & Ewer, S. M. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat. Rev. Cardiol. 7, 564-575 (2010).
    • (2010) Nat. Rev. Cardiol , vol.7 , pp. 564-575
    • Ewer, M.S.1    Ewer, S.M.2
  • 35
    • 77957355941 scopus 로고    scopus 로고
    • Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: Long-term follow-up of a prospective, randomized, multicenter trial
    • Lipshultz, S. E. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomized, multicenter trial. Lancet Oncol. 11, 950-961 (2010).
    • (2010) Lancet Oncol , vol.11 , pp. 950-961
    • Lipshultz, S.E.1
  • 36
    • 84923104065 scopus 로고    scopus 로고
    • Deep inspiration breath-hold technique for left-sided breast cancer: An analysis of predictors for organ at risk sparing
    • Register, S. et al. Deep inspiration breath-hold technique for left-sided breast cancer: an analysis of predictors for organ at risk sparing. Med. Dosim. 40, 89-95 (2015).
    • (2015) Med. Dosim , vol.40 , pp. 89-95
    • Register, S.1
  • 37
    • 0020039397 scopus 로고
    • Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer
    • Legha, S. S. et al. Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer. Cancer 49, 1762-1766 (1982).
    • (1982) Cancer , vol.49 , pp. 1762-1766
    • Legha, S.S.1
  • 38
    • 0027099925 scopus 로고
    • Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer
    • Buzdar, A. U. et al. Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer. J. Clin Oncol. 10, 1540-1546 (1992).
    • (1992) J. Clin Oncol , vol.10 , pp. 1540-1546
    • Buzdar, A.U.1
  • 39
    • 84870555288 scopus 로고    scopus 로고
    • Continuous versus bolus infusion of doxorubicin in children with ALL: Long-term cardiac outcomes
    • Lipshultz, S. E. et al. Continuous versus bolus infusion of doxorubicin in children with ALL: long-term cardiac outcomes. Pediatrics 130, 1003-1011 (2012).
    • (2012) Pediatrics , vol.130 , pp. 1003-1011
    • Lipshultz, S.E.1
  • 41
    • 85047287257 scopus 로고    scopus 로고
    • Clinical trials with pegylated liposomal doxorubicin in the treatment of ovarian cancer
    • Pisano, C. et al. Clinical trials with pegylated liposomal doxorubicin in the treatment of ovarian cancer. J. Drug Deliv. http://dx.doi.org/10.1155/2013/898146.
    • J. Drug Deliv
    • Pisano, C.1
  • 42
    • 0024531769 scopus 로고
    • A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer
    • Hortobagyi, G. N. et al. A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer. Am. J. Clin. Oncol. 12, 57-62 (1989).
    • (1989) Am. J. Clin. Oncol , vol.12 , pp. 57-62
    • Hortobagyi, G.N.1
  • 43
    • 42749100219 scopus 로고    scopus 로고
    • Different anthracycline derivatives for reducing cardiotoxicity in cancer patients
    • van Dalen, E. C., Caron, H. N. & Kremer, L. C. Different anthracycline derivatives for reducing cardiotoxicity in cancer patients. Cochrane Database Syst. Rev. 4, CD005006 (2006).
    • (2006) Cochrane Database Syst. Rev , vol.4 , pp. CD005006
    • Van Dalen, E.C.1    Caron, H.N.2    Kremer, L.C.3
  • 44
    • 0032977942 scopus 로고    scopus 로고
    • Phase i trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer
    • Sparano, J. A. et al. Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer. J. Clin. Oncol. 17, 880-886 (1999).
    • (1999) J. Clin. Oncol , vol.17 , pp. 880-886
    • Sparano, J.A.1
  • 45
    • 0030904096 scopus 로고    scopus 로고
    • Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer
    • Swain, S. M. et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J. Clin. Oncol. 15, 1318-1332 (1997).
    • (1997) J. Clin. Oncol , vol.15 , pp. 1318-1332
    • Swain, S.M.1
  • 46
    • 0026496068 scopus 로고
    • Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin
    • Hochster, H. et al. Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J. Natl. Cancer Inst. 84, 1725-1730 (1992).
    • (1992) J. Natl. Cancer Inst , vol.84 , pp. 1725-1730
    • Hochster, H.1
  • 47
    • 33845402341 scopus 로고    scopus 로고
    • Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition
    • Cardinale, D. et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114, 2472-2481 (2006).
    • (2006) Circulation , vol.114 , pp. 2472-2481
    • Cardinale, D.1
  • 48
    • 33845206791 scopus 로고    scopus 로고
    • Protective effects of carvedilol against anthracycline-induced cardiomyopathy
    • Kalay, N. et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J. Am. Coll. Cardiol. 48, 2258-2262 (2006).
    • (2006) J. Am. Coll. Cardiol , vol.48 , pp. 2258-2262
    • Kalay, N.1
  • 49
    • 84878731843 scopus 로고    scopus 로고
    • Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: The OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies)
    • Bosch, X. et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J. Am. Coll. Cardiol. 61, 2355-2362 (2013).
    • (2013) J. Am. Coll. Cardiol , vol.61 , pp. 2355-2362
    • Bosch, X.1
  • 50
    • 84881105772 scopus 로고    scopus 로고
    • Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: A systematic review and meta-analysis
    • Kalam, K. & Marwick, T. H. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur. J. Cancer 49, 2900-2909 (2013).
    • (2013) Eur. J. Cancer , vol.49 , pp. 2900-2909
    • Kalam, K.1    Marwick, T.H.2
  • 52
    • 0024422886 scopus 로고
    • Mitoxantrone: Its development and role in clinical practice
    • Weiss, R. B. Mitoxantrone: its development and role in clinical practice. Oncology 3, 135-141 (1989).
    • (1989) Oncology , vol.3 , pp. 135-141
    • Weiss R. ., B.1
  • 53
    • 0021822513 scopus 로고
    • Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: An update
    • Benjamin, R. S. et al. Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: an update. Invest. New Drugs 3, 117-121 (1985).
    • (1985) Invest. New Drugs , vol.3 , pp. 117-121
    • Benjamin, R.S.1
  • 54
    • 85066565734 scopus 로고    scopus 로고
    • FDA Novantrone®full prescribing information [online]
    • FDA Novantrone®full prescribing information [online] http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/019297s030s031lbl.pdf (2008).
    • (2008)
  • 55
    • 84897022202 scopus 로고    scopus 로고
    • Assessment and comparison of acute cardiac toxicity during high-dose cyclophosphamide and high dose etoposide stem cell mobilization regimens with N-terminal pro B type natriuretic peptide
    • Ozkan, H. A., Bal, C. & Gulbas, Z. Assessment and comparison of acute cardiac toxicity during high-dose cyclophosphamide and high dose etoposide stem cell mobilization regimens with N-terminal pro B type natriuretic peptide. Transfus. Apher. Sci. 50, 46-52 (2014).
    • (2014) Transfus. Apher. Sci , vol.50 , pp. 46-52
    • Ozkan, H.A.1    Bal, C.2    Gulbas, Z.3
  • 56
    • 84948007710 scopus 로고
    • Cardiotoxicity associated with high-dose cyclophosphamide therapy
    • Gottdiener, J. S. et al. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch. Intern. Med. 141, 758-763 (1981).
    • (1981) Arch. Intern. Med , vol.141 , pp. 758-763
    • Gottdiener, J.S.1
  • 57
    • 74049164266 scopus 로고    scopus 로고
    • The vulnerability of the heart as a pluricellular paracrine organ: Lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy
    • De Keulenaer, G. W., Doggen, K. & Lemmens, K. The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circ. Res. 106, 35-46 (2010).
    • (2010) Circ. Res , vol.106 , pp. 35-46
    • De Keulenaer, G.W.1    Doggen, K.2    Lemmens, K.3
  • 58
    • 0037172982 scopus 로고    scopus 로고
    • Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy
    • Ozcelik, C. et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc. Natl. Acad. Sci. USA 99, 8880-8885 (2002).
    • (2002) Proc. Natl. Acad. Sci. USA , vol.99 , pp. 8880-8885
    • Ozcelik, C.1
  • 59
    • 0036099675 scopus 로고    scopus 로고
    • ErbB2 is essential in the prevention of dilated cardiomyopathy
    • Crone, S. A. et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med. 8, 459-465 (2002).
    • (2002) Nat. Med , vol.8 , pp. 459-465
    • Crone, S.A.1
  • 60
    • 0035869407 scopus 로고    scopus 로고
    • Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    • Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
    • (2001) N. Engl. J. Med , vol.344 , pp. 783-792
    • Slamon, D.J.1
  • 61
    • 84907352671 scopus 로고    scopus 로고
    • Prevention of anthracycline-induced cardiotoxicity: Challenges and opportunities
    • Vejpongsa, P. & Yeh, E. T. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J. Am. Coll. Cardiol. 64, 938-945 (2014).
    • (2014) J. Am. Coll. Cardiol , vol.64 , pp. 938-945
    • Vejpongsa, P.1    Yeh, E.T.2
  • 62
    • 34548152541 scopus 로고    scopus 로고
    • Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility
    • Telli, M. L., Hunt, S. A., Carlson, R. W. & Guardino, A. E. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J. Clin. Oncol. 25, 3525-3533 (2007).
    • (2007) J. Clin. Oncol , vol.25 , pp. 3525-3533
    • Telli, M.L.1    Hunt, S.A.2    Carlson, R.W.3    Guardino, A.E.4
  • 63
    • 33748642331 scopus 로고    scopus 로고
    • Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: The M. D. Anderson Cancer Center experience
    • Guarneri, V. et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M. D. Anderson Cancer Center experience. J. Clin. Oncol. 24, 4107-4115 (2006).
    • (2006) J. Clin. Oncol , vol.24 , pp. 4107-4115
    • Guarneri, V.1
  • 64
    • 34548481766 scopus 로고    scopus 로고
    • 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity
    • de Korte, M. A. et al. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur. J. Cancer 43, 2046-2051 (2007).
    • (2007) Eur. J. Cancer , vol.43 , pp. 2046-2051
    • De Korte, M.A.1
  • 65
    • 84876526107 scopus 로고    scopus 로고
    • Cancer drugs and the heart: Importance and management
    • Suter, T. M. & Ewer, M. S. Cancer drugs and the heart: importance and management. Eur. Heart J. 34, 102-111 (2013).
    • (2013) Eur. Heart J. , vol.34 , pp. 102-111
    • Suter, T.M.1    Ewer, M.S.2
  • 66
    • 84869125207 scopus 로고    scopus 로고
    • Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer
    • Romond, E. H. et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 30, 3792-3799 (2012).
    • (2012) J. Clin. Oncol , vol.30 , pp. 3792-3799
    • Romond, E.H.1
  • 67
    • 84905858933 scopus 로고    scopus 로고
    • Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01)
    • de Azambuja, E. et al. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). J. Clin. Oncol. 32, 2159-2165 (2014).
    • (2014) J. Clin. Oncol , vol.32 , pp. 2159-2165
    • De Azambuja, E.1
  • 68
    • 84875421601 scopus 로고    scopus 로고
    • Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: A randomized, double-blind, placebo-controlled phase III study
    • Swain, S. M. et al. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. Oncologist 18, 257-264 (2013).
    • (2013) Oncologist , vol.18 , pp. 257-264
    • Swain, S.M.1
  • 69
    • 84903638071 scopus 로고    scopus 로고
    • Safety profile of pertuzumab with trastuzumab and docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: Results from the phase III trial CLEOPATRA
    • Swain, S. M. et al. Safety profile of pertuzumab with trastuzumab and docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. Oncologist 7, 693-701 (2014).
    • (2014) Oncologist , vol.7 , pp. 693-701
    • Swain, S.M.1
  • 70
    • 84880229916 scopus 로고    scopus 로고
    • Trastuzumab emtansine in the treatment of HER-2 positive metastatic breast cnacer patients
    • Bighin, C., Pronzato, P. & Del Mastro, L. Trastuzumab emtansine in the treatment of HER-2 positive metastatic breast cnacer patients. Future Oncol. 9, 955-957 (2013).
    • (2013) Future Oncol , vol.9 , pp. 955-957
    • Bighin, C.1    Pronzato, P.2    Del Mastro, L.3
  • 71
    • 44949253343 scopus 로고    scopus 로고
    • Cardiac safety of lapatinib: Pooled analysis of 3689 patients enrolled in clinical trials
    • Perez, E. A. et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin. Proc. 83, 679-686 (2008).
    • (2008) Mayo Clin. Proc , vol.83 , pp. 679-686
    • Perez, E.A.1
  • 72
    • 79953907016 scopus 로고    scopus 로고
    • Principal long-term adverse effects of imatinib in patients with chronic meloid leukemia in chronic phase
    • Mughal, T. I. & Schrieber, A. Principal long-term adverse effects of imatinib in patients with chronic meloid leukemia in chronic phase. Biologics 4, 315-323 (2010).
    • (2010) Biologics , vol.4 , pp. 315-323
    • Mughal, T.I.1    Schrieber, A.2
  • 73
    • 84901601715 scopus 로고    scopus 로고
    • Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: Final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study
    • Baccarani, M. et al. Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. Int. J. Hematol. 99, 616-624 (2014).
    • (2014) Int. J. Hematol , vol.99 , pp. 616-624
    • Baccarani, M.1
  • 74
    • 34548030470 scopus 로고    scopus 로고
    • Congestive heart failure is a rare event in patients receiving imitinib therapy
    • Atallah, E. et al. Congestive heart failure is a rare event in patients receiving imitinib therapy. Blood 110, 1233-1237 (2007).
    • (2007) Blood , vol.110 , pp. 1233-1237
    • Atallah, E.1
  • 75
    • 33746845181 scopus 로고    scopus 로고
    • Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
    • Kerkelä R. et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. 12, 908-916 (2006).
    • (2006) Nat. Med , vol.12 , pp. 908-916
    • Kerkelä, R.1
  • 76
    • 84863957259 scopus 로고    scopus 로고
    • Underestimating cardiac toxicity in cancer trials: Lessons learned? J
    • Witteles, R. M., Telli, M. Underestimating cardiac toxicity in cancer trials: lessons learned? J. Clin. Oncol. 30, 1916-1918 (2012).
    • (2012) Clin. Oncol , vol.30 , pp. 1916-1918
    • Witteles, R.M.1    Telli, M.2
  • 77
    • 79955767772 scopus 로고    scopus 로고
    • Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib
    • Fini, B. I. et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl. Cancer Inst. 103, 763-773 (2011).
    • (2011) J. Natl. Cancer Inst , vol.103 , pp. 763-773
    • Fini, B.I.1
  • 78
    • 77949890945 scopus 로고    scopus 로고
    • Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial
    • Sternberg, C. N. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 28, 1061-1068 (2010).
    • (2010) J. Clin. Oncol , vol.28 , pp. 1061-1068
    • Sternberg, C.N.1
  • 79
    • 85069330146 scopus 로고    scopus 로고
    • Cardiac safety of afatinib: Review of clinical trial data
    • Ewer, M. S., Patel, K., O'Brien, D. & Lorence, R. M. Cardiac safety of afatinib: review of clinical trial data. J. Clin. Oncol. 90 (Suppl.) S47-S48 (2014).
    • (2014) J. Clin. Oncol , vol.90 , pp. S47-S48
    • Ewer, M.S.1    Patel, K.2    O'Brien, D.3    Lorence, R.M.4
  • 80
    • 55949123335 scopus 로고    scopus 로고
    • Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma
    • Schmidinger, M. et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 26, 5204-5212 (2008).
    • (2008) J. Clin. Oncol , vol.26 , pp. 5204-5212
    • Schmidinger, M.1
  • 81
    • 64849114033 scopus 로고    scopus 로고
    • Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: Case report and review of the literature
    • Wong, M. K. K. & Jarkowski, A. Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature. Pharmacotherapy 29, 473-478 (2009).
    • (2009) Pharmacotherapy , vol.29 , pp. 473-478
    • Wong, M.K.K.1    Jarkowski, A.2
  • 82
    • 84904757283 scopus 로고    scopus 로고
    • Chemotherapy-induced cardiotoxicity: Detection, prevention and management
    • Truong, J., Yan, A. T., Cramarossa, G. & Chan, K. K. W. Chemotherapy-induced cardiotoxicity: detection, prevention and management. Can. J. Cardiol. 30, 869-878 (2014).
    • (2014) Can. J. Cardiol , vol.30 , pp. 869-878
    • Truong, J.1    Yan, A.T.2    Cramarossa, G.3    Chan, K.K.W.4
  • 83
    • 84885842429 scopus 로고    scopus 로고
    • 2013 ACCF/AHA guideline for the management of heart failure: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines
    • Yancy, C. W. et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128, 1810-1852 (2013).
    • (2013) Circulation , vol.128 , pp. 1810-1852
    • Yancy, C.W.1
  • 84
    • 0019427633 scopus 로고
    • Radiation heart disease Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3, 500 rads to the heart
    • Brosius, F. C., Waller, B. F. & Roberts, W. C. Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3, 500 rads to the heart. Am. J. Med. 70, 519-530 (1981).
    • (1981) Am. J. Med , vol.70 , pp. 519-530
    • Brosius, F.C.1    Waller, B.F.2    Roberts, W.C.3
  • 85
    • 0027386156 scopus 로고
    • Factors affecting late mortality from heart disease after treatment of Hodgkin's disease
    • Hancock, S. L., Tucker, M. A. & Hoppe, R. T. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 270, 1949-1955 (1993).
    • (1993) JAMA , vol.270 , pp. 1949-1955
    • Hancock, S.L.1    Tucker, M.A.2    Hoppe, R.T.3
  • 86
    • 34250703560 scopus 로고    scopus 로고
    • Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease
    • Heidenreich, P. A. et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. J. Clin. Oncol. 25, 43-49 (2007).
    • (2007) J. Clin. Oncol , vol.25 , pp. 43-49
    • Heidenreich, P.A.1
  • 87
    • 84898003439 scopus 로고    scopus 로고
    • Cardiovascular complications of radiation therapy for thoracic malignancies: The role for non-invasive imaging for detection of cardiovascular disease
    • Groarke, J. D. et al. Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease. Eur. Heart J. 35, 612-623 (2014).
    • (2014) Eur. Heart J. , vol.35 , pp. 612-623
    • Groarke, J.D.1
  • 89
    • 84923559134 scopus 로고    scopus 로고
    • Radiation-induced heart disease: Pathologic abnormalities and putative mechanisms
    • Taunk, N. K. et al. Radiation-induced heart disease: pathologic abnormalities and putative mechanisms. Front. Oncol. http://dx.doi.org/10.3389/fonc.2015.00039.
    • Front. Oncol
    • Taunk, N.K.1
  • 90
    • 84922967155 scopus 로고    scopus 로고
    • Valvular abnormalities detected by echocardiography in 5-year survivors of childhood cancer: A long-term follow-up study
    • Van der Pal, H. J. et al. Valvular abnormalities detected by echocardiography in 5-year survivors of childhood cancer: a long-term follow-up study. Int. J. Radiat. Oncol. Biol. Phys. 91, 213-222 (2015).
    • (2015) Int. J. Radiat. Oncol. Biol. Phys , vol.91 , pp. 213-222
    • Van Der Pal, H.J.1
  • 91
    • 0029850453 scopus 로고    scopus 로고
    • Post-radiotherapy pericarditis; A clinical and pathological study of 75 cases [French]
    • Loire, R., Fareh. S., Goineau, P., Pinede. L & Bizollon, M. H. Post-radiotherapy pericarditis; a clinical and pathological study of 75 cases [French]. Arch. Mal. Coeur Vaiss. 89, 1357-1362 (1996).
    • (1996) Arch. Mal. Coeur Vaiss , vol.89 , pp. 1357-1362
    • Loire, R.1    Fareh, S.2    Goineau, P.3    Pinede, L.4    Bizollon, M.H.5
  • 92
    • 84901285869 scopus 로고    scopus 로고
    • Radiation-induced heart disease: An under-recognized entity? Curr
    • Davis, M. & Witteles, R. M. Radiation-induced heart disease: an under-recognized entity? Curr. Treat. Options Cardiovasc. Med. 16, 317 (2014).
    • (2014) Treat. Options Cardiovasc. Med , vol.16 , pp. 317
    • Davis, M.1    Witteles, R.M.2
  • 93
    • 45849100875 scopus 로고    scopus 로고
    • Phase i trial of docetaxel and thalidomide: A regimen based on metronomic therapeutic principles
    • Sanborn, S. L. et al. Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles. Invest. New Drugs 26, 355-362 (2008).
    • (2008) Invest. New Drugs , vol.26 , pp. 355-362
    • Sanborn, S.L.1
  • 94
    • 0035880237 scopus 로고    scopus 로고
    • Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide
    • Westervelt, P. et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 98, 266-271 (2001).
    • (2001) Blood , vol.98 , pp. 266-271
    • Westervelt, P.1
  • 95
    • 84898825699 scopus 로고    scopus 로고
    • Chemotherapy and QT prolongation: Overview with clinical perspective
    • Kim, P. Y. & Ewer, M. S. Chemotherapy and QT prolongation: overview with clinical perspective. Curr. Treat. Options Cardiovasc. Med. 16, 303 (2014).
    • (2014) Curr. Treat. Options Cardiovasc. Med , vol.16 , pp. 303
    • Kim, P.Y.1    Ewer, M.S.2
  • 96
    • 84927566218 scopus 로고    scopus 로고
    • Torsade de Pointes during oral arsenic trioxide therapy for acute promyelocytic leukemia in a patient with heart failure
    • Hai, J. J. et al. Torsade de Pointes during oral arsenic trioxide therapy for acute promyelocytic leukemia in a patient with heart failure. Ann. Hematol. 94, 501-503 (2015).
    • (2015) Ann. Hematol , vol.94 , pp. 501-503
    • Hai, J.J.1
  • 97
    • 84868113707 scopus 로고    scopus 로고
    • Electrocardiograms (ECGs) in phase i anticancer drug development: The MD Anderson Cancer Center experience with 8518 ECGs
    • Naing, A. et al. Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs. Ann. Oncol. 23, 2960-2963 (2012).
    • (2012) Ann. Oncol , vol.23 , pp. 2960-2963
    • Naing, A.1
  • 98
    • 66949158016 scopus 로고    scopus 로고
    • Fluoropyrimidine-associated cardiotoxicity: Revisited
    • Saif, M. W., Shah, M. M. & Shah, A. R. Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin. Drug. Saf. 8, 191-202 (2009).
    • (2009) Expert Opin. Drug. Saf , vol.8 , pp. 191-202
    • Saif, M.W.1    Shah, M.M.2    Shah, A.R.3
  • 99
    • 22144479717 scopus 로고    scopus 로고
    • The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer
    • Ng, M., Cunningham, D. & Norman, A. R. The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer. Eur. J. Cancer 41, 1542-1546 (2005).
    • (2005) Eur. J. Cancer , vol.41 , pp. 1542-1546
    • Ng, M.1    Cunningham, D.2    Norman, A.R.3
  • 100
    • 0027069532 scopus 로고
    • Cardiotoxicity of high-dose continuous infusion fluorouracil: A prospective clinical study
    • de Forni, M. et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J. Clin. Oncol. 10, 1795-1801 (1992).
    • (1992) J. Clin. Oncol , vol.10 , pp. 1795-1801
    • De Forni, M.1
  • 101
    • 34548141828 scopus 로고    scopus 로고
    • Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab
    • Scappaticci, F. A. et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J. Natl. Cancer Inst. 99, 1232-1239 (2007).
    • (2007) J. Natl. Cancer Inst , vol.99 , pp. 1232-1239
    • Scappaticci, F.A.1
  • 102
    • 70349413045 scopus 로고    scopus 로고
    • Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: The RRiTE observational study
    • Kozloff, M. et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the RRiTE observational study. Oncologist 14, 862-870 (2009).
    • (2009) Oncologist , vol.14 , pp. 862-870
    • Kozloff, M.1
  • 103
    • 77957576145 scopus 로고    scopus 로고
    • Troponin i provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction
    • Ewer, M. S. & Ewer, S. M. Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction. J. Clin. Oncol. 28, 3901-3904 (2010).
    • (2010) J. Clin. Oncol , vol.28 , pp. 3901-3904
    • Ewer, M.S.1    Ewer, S.M.2
  • 104
    • 33344478381 scopus 로고    scopus 로고
    • Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
    • Joensuu, H. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 354, 809-820 (2006).
    • (2006) N. Engl. J. Med , vol.354 , pp. 809-820
    • Joensuu, H.1
  • 105
    • 34548531901 scopus 로고    scopus 로고
    • Tratuzumab-associated cardiac adverse effects in the Herceptin adjuvant trial
    • Suter, T. M. et al. Tratuzumab-associated cardiac adverse effects in the Herceptin adjuvant trial. J. Clin. Oncol. 25, 3859-3865 (2007).
    • (2007) J. Clin. Oncol , vol.25 , pp. 3859-3865
    • Suter, T.M.1
  • 106
    • 84884418164 scopus 로고    scopus 로고
    • 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): An open-label, randomised controlled trial
    • Goldhirsch, A. et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 382, 1021-1028 (2013).
    • (2013) Lancet , vol.382 , pp. 1021-1028
    • Goldhirsch, A.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.